16 August 2022
Convatec Group Plc
("Convatec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility ("PDMR") in ordinary shares of 10 pence each in the share capital of the Company ("Shares").
On 15 August 2022, Sten Scheibye, Non-Executive Director and PDMR, purchased 20,000 Shares at £2.37 per Share. Sten Scheibye’s resulting shareholding is 45,000 Shares.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Sten Scheibye
|
|
2
|
Reason for the notification
|
|
a)
|
Position/Status
|
Non-Executive Director
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Convatec Group Plc
|
|
b)
|
LEI
|
213800LS272L4FIDOH92
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 10p each in Convatec Group Plc (“Shares”)
GB00BD3VFW73
|
|
b)
|
Nature of the transaction
|
Purchase of shares on 15 August 2022
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
£2.37
|
Volume(s)
20,000
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
20,000
£47,400
|
|
e)
|
Date of the transaction
|
2022-08-15
|
|
f)
|
Place of the transaction
|
London Stock Exchange, Main Market (XLON)
|
|
|
|
|
|
|
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations, Convatec +44 (0)782 644 7807
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
Convatec Group Plc’s LEI code is 213800LS272L4FIDOH92
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a FTSE 250 global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Group revenues in 2021 were over $2 billion. With around 10,000 colleagues, we provide our products and services in over 100 countries, united by a promise to be forever caring. Our products provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. To learn more about Convatec, please visit http://www.convatecgroup.com
